Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 25
- Registration Number
- NCT00411762
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1035
- Registration Number
- NCT00411229
- Locations
- 🇨🇳
Sanofi-Aventis, Taipei, Taiwan
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00408772
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1206
- Registration Number
- NCT00408408
- Locations
- 🇺🇸
Iredell Memorial Hospital, Statesville, North Carolina, United States
🇺🇸Hattiesburg Clinic, PA at Forrest General, Hattiesburg, Mississippi, United States
🇺🇸Cancer Care Center, Incorporated, Salem, Ohio, United States
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 39
- Registration Number
- NCT00408564
- Locations
- 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 36
- Registration Number
- NCT00403429
- Locations
- 🇮🇹
Clinica Malzoni, Reparto di Ginecologia Oncologica, Avellino, AV, Italy
🇮🇹Ospedale Ramazzini, Day Hospital Oncologico, Carpi, MO, Italy
🇮🇹IRCCS Oncologico Bari, Oncologia Medica, Bari, BA, Italy
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 381
- Registration Number
- NCT00398879
- Locations
- 🇺🇸
AOI Pharmaceuticals Investigative Site, Appleton, Wisconsin, United States
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Pamela L. Kunz
- Target Recruit Count
- 40
- Registration Number
- NCT00398320
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
- Conditions
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Medstar Health Research Institute
- Registration Number
- NCT00397761
- Locations
- 🇺🇸
Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States
Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer
- Conditions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 164
- Registration Number
- NCT00383695
- Locations
- 🇬🇧
Dorset Cancer Centre, Poole Dorset, England, United Kingdom
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇸🇪Karolinska University Hospital - Solna, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.